Like a number of the other biotech startups to reach Wall Street this year, Acrivon is primarily focused on a single drug and getting it to market.
Its lead drug is prexasertib, a small molecule targeting a pair of enzymes called CHK1 and CHK2 that was discovered by Array BioPharma in the 2000s and later licensed by Lilly. The pharmaceutical firm shelved it after more than a dozen clinical trials.
Acrivon’s bet is that it can better identify patients who will respond to treatment. The company is working with Akoya Biosciences to develop a companion diagnostic test.
